

Truncated cinchona alkaloids as catalysts in enantioselective monobenzoylation of meso 1,2-diols

E. Peter Kündig,* Alvaro Enriquez Garcia, Thierry Lomberget, Pablo Perez Garcia, and Patrick Romanens

Department of Organic Chemistry, University of Geneva, 1211 Gweneva 4, Switzerland
peter.kündig@chiorg.unige.ch

Electronic Supplementary Information

General.

Liquids were distilled under N₂ from CaH₂ in an H-tube prior to use. Molecular sieves (4Å) were activated by heating at 160 °C under high vacuum for 12 hours. NOTE: Diamines **5** and **7** slowly reacted when dissolved in CH₂Cl₂ to give the corresponding chloromethylene chloride salt.¹ Solvents were purified by filtration on drying columns using Solvtek[®] system. Chemicals were purchased from Aldrich, Fluka, Acros, Lancaster, TCI organics or Buchler GmbH and used without further purification unless noted. Reactions and manipulations involving organometallic or moisture sensitive compounds were carried out under N₂ atmosphere and glassware was previously dried by heating under high vacuum as necessary. Celite 545 was used as filtering material. Yields refer to homogeneous material purified by crystallisation or Flash column chromatography using Brunschwig silica gel 60 Å (32-63 mesh) or Acros neutral Alumina (50-200 micron). Proton and carbon NMR spectra were recorded on Bruker AMX-500, AMX-400 or AMX-300 FT spectrometers using an internal deuterium lock. Chemical shifts are quoted in parts per million (ppm) downfield of TMS. Coupling constants *J* are quoted in Hz. Carbon NMR and DEPT-135 spectra were recorded with broad band proton decoupling. IR spectra were recorded on a Perkin-Elmer Spectrum One spectrophotometer. Analytical HPLC was performed using an Agilent 1100 series. Electron impact (EI) mass spectra were obtained using Varian CH-4 or SM-1 instruments operating at 40-70eV and for Electrospray ionization (ESI) HRMS analyses were measured on a VG analytical 7070E instrument. Optical rotations were measured at 20°C on a Perkin Elmer 241 polarimeter using a quartz cell (*l* = 10 cm) with a Na high pressure lamp (λ = 589 nm). Melting points were determined on a Büchi 510 apparatus and are

uncorrected.



(2*S*,4*S*,5*R*)-*N,N*-Dimethyl-2-aminomethyl-5-ethenyl-quinuclidine.

A Schlenk tube equipped with a reflux condenser was rapidly charged with (2*S*,4*S*,5*R*)-2-aminomethyl-5-ethenyl-quinuclidine² (**4**) (1.41 g, 8.51 mmol), evacuated for 30 seconds, filled with N₂, and cooled to 0 °C. Then 98 % formic acid (2.04 mL, 54.1 mmol) and 36.5 % aq. formaldehyde (1.74 mL, 24.5 mmol) were added sequentially and the mixture was refluxed for 3 h. The reaction was cooled to r.t. and dissolved in a solution (1M) of HCl (30 mL) and extracted with Et₂O (3 x). The aqueous layer was then brought up to pH ≈12 with K₂CO₃ and extracted with Et₂O (3 x). The combined organic layers were dried with anh. Na₂SO₄ and volatiles removed under low pressure to give the title compound (1.56 g, 94 % yield) as a colourless oil.

MW = 194.34 g / mol; **R_F** = 0.58 (CHCl₃ 84%; MeOH 14%; NH_{3(aq)} 2%); [α]_D²⁰: +46 (c = 1.64 CHCl₃); **IR** (neat, cm⁻¹): 3340, 3075, 2934, 2860, 2818, 2764, 1636, 1454, 1320, 1263, 1163, 1123, 1027, 990, 908; **¹H NMR** (400 MHz, CDCl₃): δ 5.84 (ddd, *J* = 17.2, 10.3 and 7.6 Hz, 1H), 5.02-4.94 (m, 2H), 3.13 (dd, *J* = 13.8 and 10.1, 1H), 2.94-2.79 (m, 2H), 2.65-2.57 (m, 2H), 2.42 (dd, *J* = 12.5 and 8.3, 1H), 2.26-2.20 (m, 1H), 2.19 (s, 6H), 2.07 (dd, *J* = 12.5 and 6.5, 1H), 1.86-1.79 (m, 1H), 1.70-1.65 (m, 1H), 1.48-1.41 (m, 2H), 0.89 (dddd, *J* = 13.3, 6.7, 2.5 and 1.7, 1H); **¹³C NMR** (125 MHz, CDCl₃): δ 142.2, 114.1, 64.1, 56.2, 53.6, 45.9, 40.8, 39.9, 28.9, 27.8, 27.4; **HRMS** (ESI) calcd. for C₁₂H₂₃N₂ [M+H]⁺: 195.1855, found: 195.1861.

(2*S*,4*S*,5*R*)-*N,N*-Dimethyl-2-aminomethyl-5-ethylquinuclidine (5**).**

A two neck round bottom flask equipped charged with (2*S*,4*S*,5*R*)-*N,N*-dimethyl-2-aminomethyl-5-ethene-quinuclidine (1.12 g, 5.80 mmol) and 10 % Pd/Cl (123 mg, 0.12 mmol). The flask was evacuated and refilled with H₂ from a balloon. Then MeOH (27 mL) was added and the suspension was stirred at r.t. for 16 h. The reaction mixture was filtered




and the solvent evaporated under reduced pressure. The residue was dissolved aq. HCl (1M, 45 mL) and extracted with Et₂O (3 x). The aqueous layer was then brought to pH ≈ 12 with K₂CO₃ and extracted with Et₂O (3 x). The combined organic layers were dried with anh. Na₂SO₄ and volatiles removed under low pressure to give the title compound **5** (1.13 g, 95 % yield) as a colourless oil.

MW = 196.34 g / mol; **R_F** = 0.64 (CHCl₃ 84%; MeOH 14%; NH_{3(aq)} 2%); [α]_D²⁰: +12 (*c* = 0.70 CHCl₃); **IR** (CHCl₃, cm⁻¹): 3137, 2934, 2864, 2775, 2822, 1457, 1379, 1264, 1093, 1027. **¹H NMR** (400 MHz, CDCl₃): δ 3.17 (dd, *J* = 13.5 and 9.4, 1H), 2.98-2.81 (m, 2H), 2.71-2.60 (m, 1H), 2.42 (dd, *J* = 12.3 and 8.0, 1H), 2.46-2.36 (m, 1H), 2.22 (s, 6H), 2.14 (dd, *J* = 12.3 and 6.8, 1H), 1.85-1.76 (m, 1H), 1.70-1.64 (m, 1H), 1.57-1.30 (m, 5H), 0.87-0.96 (m, 1H), 0.86 (t, *J* = 7.2, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 64.2, 57.8, 53.6, 46.1, 41.0, 37.4, 28.6, 27.6, 27.2, 25.6, 12.2; **HRMS** (ESI) calcd. for C₁₂H₂₅N₂ [M+H]⁺: 197.2012, found: 197.2013.

(2*R*,4*S*,5*R*)-*N,N*-Dimethyl-2-aminomethyl-5-ethenyl-quinuclidine

A Schlenk tube equipped with a reflux condenser was rapidly charged with (2*R*,4*S*,5*R*)-2-aminomethyl-5-ethenyl-quinuclidine² (1.00 g, 6.03 mmol), evacuated for 30 seconds, filled with N₂, and cooled at 0 °C. Then 98 % formic acid (1.39 mL, 36.0 mmol) and 36.5 % formaldehyde (1.22 mL, 16.4 mmol) were added and the mixture was refluxed for 3 h. Then cooled at r.t., dissolved in a solution (1M) of HCl (30 mL) and extracted with Et₂O (3 x). The aqueous layer was brought to pH ≈ 12 with K₂CO₃ and extracted with Et₂O (3 x). The combined organic layers were dried with anh. Na₂SO₄ and volatiles removed under low pressure to give the title compound (1.10 g, 94 % yield) as colourless oil.

MW = 194.34 g / mol; **R_F** = 0.58 (CHCl₃ 84%; MeOH 14%; NH_{3(aq)} 2%); [α]_D²⁰: + 181 (*c* = 1.64 CHCl₃); **IR** (neat, cm⁻¹): 3076, 2934, , 2862, 2818, 2763, 1682, 1636, 1455, 1321, 1263, 1202, 1029; **¹H NMR** (400 MHz, CDCl₃): δ 5.86 (ddd, *J* = 17.4, 9.9 and 7.3, 1H), 5.02-4.99 (m, 1H), 4.98-4.96 (m, 1H), 2.96-2.78 (m, 4H), 2.67-2.61 (m, 1H), 2.42 (dd, *J* = 12.5 and 8.2, 1H), 2.23-2.16 (m, 1H), 2.21 (s, 6H), 2.11 (dd, *J* = 12.5 and 6.4, 1H), 1.70-1.66 (m, 1H), 1.61-1.46 (m, 3H), 1.26 (dd, *J* = 21.6, 8.2, 2.0 and 1.8, 1H); **¹³C NMR** (125 MHz, CDCl₃): δ 141.7, 114.5, 63.1, 53.7, 49.6, 47.7, 46.2, 40.6, 28.0,



27.2, 27.1; **HRMS** (ESI) calcd. for $C_{12}H_{23}N_2 [M+H]^+$: 195.1855, found: 195.1848.


(2*R*,4*S*,5*R*)-*N,N*-Dimethyl-2-aminomethyl-5-ethylquinuclidine (7).

A two neck round bottom flask was charged with (2*R*,4*S*,5*R*)-*N,N*-dimethyl-2-aminomethyl-5-ethenyl-quinuclidine (1.11 g, 5.66 mmol) and 10 % palladium on charcoal (120 mg, 0.11 mmol). The flask was evacuated and refilled with H_2 from a balloon. Then MeOH (26 mL) was added and the suspension was stirred at r.t. for 18 h. The reaction mixture was then filtered and the solvent evaporated under reduced pressure. The residue was dissolved in aq. HCl (1 M, 45 mL) and extracted with Et₂O (3 x). The aqueous layer was brought to pH ≈ 12 with K₂CO₃ and extracted with Et₂O (3 x). The combined organic layers were dried with anh. Na₂SO₄ and volatiles removed under low pressure to give the title compound **7** (933 mg, 84 %) as colourless oil.

MW = 196.34 g / mol; **R_F** = 0.46 (CHCl₃ 84%; MeOH 14%; NH_{3(aq)} 2%); $[\alpha]_D^{20}$: + 128 (*c* = 0.93 CHCl₃); **IR** (neat, cm⁻¹): 2933, 2860, 2817, 2764, 1683, 1456, 1378, 1325, 1263, 1202, 1147, 1034; **¹H NMR** (400 MHz, CDCl₃): δ 2.90-2.73 (m, 4H), 2.39 (dd, *J* = 12.4 and 7.9, 1H), 2.35 (ddd, *J* = 14.0, 7.3 and 2.3, 1H), 2.20 (s, 6H), 2.11 (dd, *J* 12.4 and 6.8, 1H), 1.62-1.51 (m, 2H), 1.49-1.40 (m, 2H), 1.39-1.25 (m, 3H), 1.24-1.15 (m, 1H), 0.82 (t, *J* 7.3, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 63.2, 53.7, 49.5, 49.2, 46.1, 37.9, 27.8, 26.7, 26.1, 25.8, 12.1; **HRMS** (ESI) calcd. for $C_{12}H_{25}N_2 [M+H]^+$: 197.2017, found: 197.2005.


General procedure for the asymmetric acylation of meso-1,2-diols.

A solution of chiral diamine **5** (3.4 mg, 0.017 mmol, 2 mol %) in dry AcOEt (2 ml) was added under N₂ to a mixture of meso-1,2-diol (0.86 mmol) and activated molecular sieves (4 Å, 113 mg) in dry AcOEt (6 ml). To the stirred, cold (-60 °C) solution, benzoyl chloride (150 µL, 1.29 mmol) followed by Et₃N (121 µL, 0.86 mmol) were added drop-wise. The resulting mixture was stirred at -60 °C for 22 hours, then quenched with a solution (10 mL) of phosphate buffer (pH = 7) and extracted with Et₂O (3 x). The organic layers were dried with MgSO₄ and all volatiles were removed under reduced pressure. The residue was purified by flash chromatography (Et₂O / pentane) to the monobenzoate.




7

(+)-(1*S*,2*R*)-2-Hydroxy-1-cyclohexyl benzoate (+)-9^{3,4}




Colourless oil; **MW** = 220.26 g / mol; **R_F** = 0.16 (Et₂O / pentane, 1 : 3); **[α]_D²⁰**: +16 (*c* = 0.68 CHCl₃); **IR** (neat, cm⁻¹): 3441, 2937, 2862, 1715, 1602, 1450, 1272; **¹H NMR** (300 MHz, CDCl₃): δ 8.03-7.99 (m, 2H), 7.60-7.53 (m, 1H), 7.48-7.40 (m, 2H), 5.24-5.20 (m, 1H), 3.99-3.92 (m, 1H), 2.09-1.92 (m, 1H), 1.95 (broad s, 1H), 1.90-1.80 (m, 1H), 1.78-1.62 (m, 4H), 1.51-1.37 (m, 2H); **¹³C NMR** (100 MHz, CDCl₃): δ 166.3, 133.1, 130.4, 129.6, 128.4, 74.6, 70.0, 30.4, 27.4, 21.8, 21.6; **MS m/z** (EI): 202 (2 [M-H₂O]⁺), 174 (2), 149 (4), 115 (14), 105 (100), 98 (95 [M-BzOH]⁺), 77 (79), 51 (36); **HPLC** Chiralcel OJ-H, eluent: 95:5 hexane / ⁱPrOH, flow rate: 1 mL / min: retention times 11.3 min ((1*S*,2*R*)-enantiomer) and 13.5 min ((1*R*,2*S*)-enantiomer).

cis-1,2-Dibenzoyloxycyclohexane (10)⁵



White solid; **MW** = 324.37 g / mol; **R_F** = 0.48 (Et₂O / pentane, 1: 3); **MP** = 63-64 °C (Ethanol); **IR** (neat, cm⁻¹): 2942, 1786, 1720, 1600, 1450, 1265, 1210; **¹H NMR** (400 MHz, CDCl₃): δ 8.01 (d, *J* 7.1, 4H), 7.54 (t, *J* 8.8, 2H), 7.41 (t, *J* 8.8, 4H), 5.40-5.38 (m, 2H), 2.14-2.06 (m, 2H), 1.90-1.75 (m, 4H), 1.62-1.53 (m, 2H); **¹³C NMR** (100 MHz, CDCl₃): δ 165.8, 132.9, 130.5, 129.6, 128.3, 71.9, 28.0, 21.9; **MS m/z** (EI): 202 (12 [M-BzOH]⁺), 198 (15), 182 (5), 122 (3), 105 (100), 77 (81), 51 (62).


(+)-(2*S*,3*R*)-3-Hydroxyl-2-butyl benzoate (19)⁶:



The starting material was dried over MS 4Å in CH₂Cl₂ solution.
(+)-19: colourless oil; **MW** = 194.23 g / mol; **R_F** = 0.26 (Et₂O / pentane, 1 : 3); **[α]_D²⁰**: + 17 (*c* = 0.70 CH₂Cl₂); **IR** (neat, cm⁻¹): 3441, 2981, 1714, 1451, 1315, 1275, 1119, 1091, 1071, 1026, 1008; **¹H NMR** (400 MHz, CDCl₃): δ 8.03 (d, *J* 7.8, 2H), 7.54 (t, *J* 7.2, 1H), 7.42 (t, *J* 7.8, 2H), 5.15-5.07 (m, 1H), 3.99 (cd, *J* 6.4 and 3.5, 1H), 2.35 (broad s, 1H), 1.33 (d, *J* 6.4, 3H), 1.23 (d, *J* 6.4, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 166.2, 133.1,


130.3, 129.6, 128.4, 75.1, 69.8, 18.0, 14.5; **MS** *m/z* (EI): 194 (2 [M]⁺), 179 (2), 150 (48), 105 (100), 77 (80), 72 (32), 51 (14). **HPLC** Chiralcel OJ-H, eluent: 95:5 hexane / ⁱPrOH, flow rate: 1 mL / min: retention times 10.6 min ((2*S*,3*R*)-enantiomer) and 12.0 min ((2*R*,3*S*)-enantiomer).

cis-1,2-Bisbenzoyloxybutane⁷



Colourless oil; **MW** = 298.34 g / mol; **R_F** = 0.65 (Et₂O / pentane, 1 : 3); **MP** = 73-75 °C (CH₂Cl₂ / cyclohexane); **IR** (neat, cm⁻¹): 2988, 1787, 1717, 1692, 1601, 1584, 1451, 1316, 1266, 1212, 1113, 1096, 1070, 1038, 1016, 996; **¹H NMR** (400 MHz, CDCl₃): δ 8.04 (d, *J* 8.3, 4H), 7.55 (t, *J* 7.5, 2H), 7.43 (t, *J* 7.7, 4H), 5.42-5.36 (m, 2H), 1.45 (d, *J* 6.4, 6H); **¹³C NMR** (100 MHz, CDCl₃): δ 166.0, 133.2, 130.5, 129.8, 128.6, 72.5, 15.7; **MS** *m/z* (EI): 254 (6), 226 (6), 210 (27), 198 (12), 176 (14 [M-PhCOOH]⁺), 149 (13), 132 (12), 105 (100), 77 (70), 51 (47).


(+)-(1*S*,2*R*)-2-Hydroxy-1-cyclopentyl benzoate (20)^{3,8,9}



The starting material was dried over MS 4Å in CH₂Cl₂ solution.^[3, 12, 13] colourless oil; **MW** = 206.24 g / mol; **R_F** = 0.22 (Et₂O / pentane, 1 : 3); **[α]²⁰_D**: +13 (*c* = 0.45 CH₂Cl₂); **IR** (neat, cm⁻¹): 3596, 3064, 2974, 2879, 1717, 1602, 1584, 1451, 1272, 1117; **¹H NMR** (300 MHz, CDCl₃): δ 8.03 (dd, *J* 8.3, and 1.1, 2H), 7.36 (dt, *J* 7.5 and 1.5, 1H), 7.41 (dt, *J* 7.5 and 1.5, 2H), 5.24-5.16 (m, 1H), 4.32-4.25 (m, 1H), 2.64 (broad s, 1H), 2.19-1.99 (m, 1H), 1.98-1.87 (m, 3H), 1.82-1.75 (m, 1H), 1.64-1.57 (m, 1H); **¹³C NMR** (75 MHz, CDCl₃): δ 166.4, 133.1, 130.1, 129.6, 128.4, 77.4, 73.4, 30.9, 28.2, 19.5; **MS** *m/z* (EI): 206 (1 [M]⁺), 198 (14), 188 (34 [M-H₂O]⁺), 106 (50), 105 (100), 77 (73), 51 (50); **HRMS** (ESI) calcd. for C₁₂H₁₄O₃Na [M+Na]⁺: 229.0835, found: 229.0829; **HPLC** Chiralcel OJ-H, eluent: 95:5 hexane / ⁱPrOH, flow rate: 0.5 mL / min: retention times 22.3 min ((1*S*,2*R*)-enantiomer) and 26.7 min ((1*R*,2*S*)-enantiomer).


cis-1,2-Bisbenzoyloxcyclopentane¹¹

White solid; **MW** = 310.35 g / mol; **R_F** = 0.59 (Et₂O / pentane, 1 : 3); **MP** = 45-47 °C




(ethanol); **IR** (neat, cm⁻¹): 3065, 2962, 1720, 1602, 1584, 1451, 1315, 1283, 1272, 1258, 1177, 1122; **¹H NMR** (300 MHz, CDCl₃): δ 7.97 (dd, *J* 8.5, and 1.3, 4H), 7.52 (tt, *J* 7.5, and 1.5, 2H), 7.40-7.33 (m, 4H), 5.54-5.48 (m, 2H), 2.27-2.13 (m, 2H), 2.10-1.97 (m, 3H), 1.84-1.72 (m, 1H); **¹³C NMR** (125 MHz, CDCl₃): δ 165.9, 132.8, 130.5, 129.6, 128.2, 75.1, 28.6, 19.7; **MS m/z** (ESI): 311 (100 [M]⁺), 205 (24), 189 (99), 106 (8); **HRMS** (ESI) calcd. for C₁₉H₁₉O₄ [M+H]⁺: 311.1277, found: 311.1277.

(+)-4-Anhydro-2-acyloxyerytritol (21):



proposed absolute configuration

White solid, **MW** = 208.22 g / mol; **R_F** = 0.07 (Et₂O / pentane, 1 : 2); **[α]_D²⁰**: +4 (*c* = 0.86 CH₂Cl₂); **MP** = 80-81 °C (CH₂Cl₂, cyclohexane); **IR** (neat, cm⁻¹): 3417, 2926, 2874, 1715, 1601, 1584, 1451, 1269, 1177, 1118, 1068; **¹H NMR** (400 MHz, CDCl₃): δ 8.05-8.00 (m, 2H), 7.58-7.52 (m, 1H), 7.37-7.34 (m, 2H), 5.34-5.30 (m, 1H), 4.51 (ddd, *J* 11.1, 5.5 and 1.6, 1H), 4.11 (ddd, *J* 10.2, 5.8 and 1.7, 1H), 3.98 (ddd, *J* 9.3, 5.8 and 9.3, 1H), 3.96 (ddd, *J* 12.1, 5.8 and 1.7, 1H), 3.74 (ddd, *J* 9.3, 5.5 and 1.8, 1H), 2.83 (broad s, 1H); **¹³C NMR** (125 MHz, CDCl₃): δ 166.6, 133.7, 130.0, 129.6, 128.7, 74.5, 72.6, 71.2, 70.7; **HRMS** (ESI) calcd. for C₁₁H₁₃O₄ [M⁺+H]: 209.0808, found: 209.0817; **HPLC** Chiralcel AS-H, eluent: 95:5 hexane / ⁱPrOH, flow rate: 1 mL / min: retention times 38.1 min ((-)-enantiomer) and 45.6 min ((+)-enantiomer).




cis-1,2-Bisbenzoyloxy-4-anhydroerytritol¹³

Colourless oil; **MW** = 312.33 g / mol; **R_F** = 0.40 (Et₂O / pentane, 1 : 2); **IR** (neat, cm⁻¹): 2925, 2872, 1721, 1602, 1584, 1491, 1451, 1345, 1315, 1277, 1177, 1126; **¹H NMR** (400 MHz, CDCl₃): δ 7.98-7.93 (m, 4H), 7.56-7.50 (m, 2H), 7.39-7.32 (m, 4H), 5.70-5.66 (m, 2H), 5.32-5.26 (m, 2H), 4.08-4.03 (m, 2H); **¹³C NMR** (100 MHz, CDCl₃):


δ 166.1, 133.6, 130.1, 129.7, 128.7, 72.6, 70.9; **HRMS** (ESI) calcd. for C₁₈H₁₇O₅ [M⁺+H]: 313.1070, found: 313.1066.

(+)-(1S,2R)- 2-Hydroxy-1-cyclohex-4-enyl benzoate (22)¹⁰



Colourless oil; **MW** = 218.25 g / mol; **R_F** = 0.08 (Et₂O / pentane, 1 : 3); $[\alpha]_D^{20}$: + 44 (*c* = 0.92 CH₂Cl₂); **IR** (neat, cm⁻¹): 3597, 3064, 3036, 2929, 2853, 1716, 1602, 1584, 1451, 1315, 1275, 1116; **¹H NMR** (500 MHz, CDCl₃): δ 8.04 (d, *J* 7.9, 2H), 7.58-7.52 (m, 1H), 7.46-7.40 (m, 2H), 5.70-5.58 (m, 2H), 5.35-5.30 (m, 1H), 4.18-4.14 (m, 1H), 2.64 (broad s, 1H), 2.52-2.43 (m, 3H), 2.39-2.32 (m, 1H); **¹³C NMR** (125 MHz, CDCl₃): δ 166.6, 133.2, 130.3, 129.7, 128.4, 123.9, 123.4, 72.8, 67.6, 31.5, 28.4; **MS m/z** (EI): 218 (2 [M]⁺), 164 (2), 123 (18), 105 (100), 96 (84), 77 (19), 67 (17), 51 (11); **HRMS** (ESI) calcd. for C₁₃H₁₅O₃ [M+H]⁺: 219.1015, found: 219.1009; **HPLC** Chiralcel OJ-H, eluent: 95:5 hexane / ⁱPrOH, flow rate: 0.5 mL / min: retention times 25.3 min ((1S,2R)-enantiomer) and 31.4 min ((1R,2S)-enantiomer).


cis-1,2-Bisbenzoyloxycyclo-4-hexene



Conversion: 8 % (**¹H-NMR**): colourless oil; **MW** = 322.36 g / mol; **R_F** = 0.47 (Et₂O / pentane, 1 : 3); **IR** (neat, cm⁻¹): 3065, 3038, 2934, 1718, 1584, 1452, 1315, 1303, 1280, 1266, 1253, 1217; **¹H NMR** (500 MHz, CDCl₃): δ 8.03-8.01 (m, 4H), 7.57-7.51 (m, 2H), 7.43-7.40 (m, 4H), 5.73 (t, *J* 1.6, 2H), 5.80-5.55 (m, 2H), 2.68-2.56 (m, 4H); **¹³C NMR** (125 MHz, CDCl₃): δ 165.9, 132.9, 130.2, 129.6, 128.3, 123.6, 69.9, 28.8; **HRMS** (ESI) calcd. for C₂₀H₁₉O₄ [M+H]⁺: 323.1277, found: 323.1279.


(+)-(1S,2R)- 2-Hydroxyl-1-cyclooctanyl benzoate (23)³

Colourless oil; **MW** = 248.32 g / mol; **R_F** = 0.40 (Et₂O / pentane, 1: 2). $[\alpha]^{20}_D$: + 8 (*c* = 0.90 CH₂Cl₂); **IR** (neat, cm⁻¹): 3425, 3036, 2922, 2856, 1710, 1601, 1584, 1450, 1315, 1271, 1176, 1110. **¹H NMR** (400 MHz, CDCl₃): δ 8.05-8.01 (m, 2H), 7.56-7.52 (m, 1H), 7.45-7.39 (m, 2H), 5.32-5.27 (m, 1H), 4.07 (ddd, *J* 6.4, 3.9, 2.4, 1H) 2.39 (broad s, 1H),




2.23-2.11 (m, 1H), 1.94-1.47 (m, 11H); **¹³C NMR** (100 MHz, CDCl₃): δ 166.1, 132.9, 130.3, 129.5, 128.3, 77.6, 71.7, 30.5, 27.8, 26.8, 25.6, 24.1, 22.0; **HRMS** (ESI) calcd. for C₁₅H₂₁O₃ [M+H]⁺: 249.1485, found: 249.1481; **HPLC** Chiralcel OJ-H, eluent: 95:5 hexane / ⁱPrOH, flow rate: 1 mL / min: retention times 8.9 min ((1*S*,2*R*)-enantiomer) and 10.7 min ((1*R*,2*S*)-enantiomer).

cis-1,2-Bisbenzoyloxycyclooctane:




Colourless oil; **MW** = 352.43 g / mol; **R_F** = 0.44 (Et₂O / pentane, 1 : 4); **IR** (neat, cm⁻¹): 3422, 2924, 2853, 1717, 1451, 1378, 1314, 1278, 1176, 1109, 1069, 1026; **¹H NMR** (400 MHz, CDCl₃): δ 8.03-7.98 (m, 4H), 7.57-7.51 (m, 2H), 7.43-7.38 (m, 4H), 5.54-5.49 (m, 2H), 2.30-1.19 (m, 2H), 1.96-1.64 (m, 10H); **¹³C NMR** (100 MHz, CDCl₃): δ 166.2, 133.2, 130.8, 130.0, 128.7, 75.0, 29.1, 26.7, 23.8; **HRMS** (ESI) calcd. for C₂₂H₂₅O₄ [M+H]⁺: 353.1747, found: 353.1745.

(+)-(2*S*,3*R*)-1,4-Bisbenzyloxy-3-hydroxyl-2-butyl benzoate (24):




Colourless oil; **MW** = 406.48 g / mol; **R_F** = 0.16 (Et₂O / pentane, 1 : 2); **[α]_D²⁰**: + 55 (c = 0.23 CH₂Cl₂); **IR** (neat, cm⁻¹): 3464, 3063, 3031, 2865, 1716, 1452, 1270, 1108, 1070, 1026, 737, 712, 698; **¹H NMR** (400 MHz, CDCl₃): δ 8.03 (d, *J* 8.3, 2H), 7.58 (t, *J* 7.4, 1H), 7.43-7.41 (m, 2H), 7.31-7.22 (m, 10H), 5.33 (ddd, *J* 6.7, 4.7, and 3.5, 1H), 4.61-4.49 (m, 4H), 4.27-4.19 (m, 1H), 3.91 (dd, *J* 10.9 and 4.8, 1H), 3.84 (dd, *J* 10.9 and 3.5, 1H), 3.65 (dd, *J* 9.7 and 3.9, 1H), 3.60 (dd, *J* 9.5 and 5.9, 1H), 2.87 (d, *J* 5.7, 1H); **¹³C NMR** (125 MHz, CDCl₃): δ 165.7, 130.8, 137.7, 133.1, 129.9, 129.7, 128.4, 128.37, 128.33, 127.8, 127.7, 127.6, 127.5, 73.4, 73.3, 73.0, 70.6, 69.8, 68.8; **HRMS** (ESI) calcd. for C₂₅H₂₇O₅ [M+H]⁺: 407.1853, found: 407.1862; **HPLC** Chiralcel AS-H, Gradient 99:1 to 90:10 during 60 min, eluent: hexane / ⁱPrOH, flow rate: 1 mL / min: retention times 35.8 min ((2*S*,3*R*)-enantiomer) and 42.6 min ((2*R*,3*S*)-enantiomer).

cis-2,4-Bisbenzoyloxy-1,4-benzylloxybutane




White solid; **MW** = 510.59 g / mol; **R_F** = 0.51 (Et₂O / pentane, 1 : 2); **MP** = 114-116 °C (CH₂Cl₂ / cyclohexane); **IR** (neat, cm⁻¹): 3064, 3032, 2928, 2856, 1788, 1719, 1601, 1585, 1451, 1258, 1096; **¹H NMR** (400 MHz, CDCl₃): δ 8.03-7.99 (m, 4H), 7.57 (tt, *J* 7.5 and 1.3, 2H), 7.44 (t, *J* 7.8, 4H), 7.27-7.18 (m, 10H), 5.76-7.72 (m, 2H), 4.56 (d, *J* 12.1, 2H), 4.48 (d, *J* 12.1, 2H), 3.88 (dd, *J* 10.8 and 3.8, 2H), 3.82 (dd, *J* 10.8 and 3.8, 2H); **¹³C NMR** (125 MHz, CDCl₃): δ 165.5, 138.0, 133.4, 130.2, 130.1, 128.7, 128.6, 128.0, 127.9, 77.3, 73.8, 68.4; **MS m/z** (EI): 403 (2 [M-BnO]⁺), 313 (65), 267 (2), 191 (5), 158 (4), 105 (100), 91 (84); **HRMS** (EI) calcd. for C₂₅H₂₃O₅ [M-BnO]⁺: 403.1545, found: 403.1544.

(+)-(2*S*,3*R*)-3-Hydroxyl-2-tetralinyl benzoate (25):



Colourless oil; **MW** = 268.32 g / mol; **R_F** = 0.20 (Et₂O / pentane, 1 : 2); **[α]_D²⁰**: + 20 (*c* = 0.69 CH₂Cl₂), 81.7 % ee; **IR** (neat, cm⁻¹): 3423, 3064, 2931, 1712, 1601, 1583, 1495, 1451, 1315, 1270, 1113, 1068; **¹H NMR** (400 MHz, CDCl₃): δ 8.06-8.01 (m, 2H), 7.58-7.52 (m, 1H), 7.41 (t, *J* 7.8, 2H), 7.20-7.10 (m, 4H), 5.55-5.50 (m, 1H), 4.37-4.32 (m, 1H), 3.31-3.04 (m, 4H), 2.75 (broad s, 1H); **¹³C NMR** (100 MHz, CDCl₃): δ 166.9, 133.5, 133.2, 132.7, 130.2, 130.0, 129.5, 129.2, 128.6, 126.6, 126.5, 73.3, 68.1, 34.9, 32.1; **MS m/z** (EI): 146 (100 [M-PhCOOH]⁺), 145 (56), 128 (55), 117 (60), 105 (88), 77 (69). **HRMS** (ESI) calcd. for C₁₇H₁₇O₃ [M+H]⁺: 269.1172, found: 269.1179; **HPLC** Chiralcel AS-H, Gradient 99:1 to 90:10 during 60 min, eluent: hexane / ⁱPrOH, flow rate: 1 mL / min: retention times 35.6 ((2*S*,3*R*)-enantiomer) min and 47.7 min((2*R*,3*S*)-enantiomer).



cis-2,4-Bisbenzoyloxytetralin.

White solid; **MW** = 372.42 g / mol; **R_F** = 0.69 (Et₂O / pentane, 1 : 2); **MP** = 91 °C (Ethanol); **IR** (neat, cm⁻¹): 3066, 1787, 1720, 1600, 1584, 1451, 1315, 1278, 1212, 1174, 1109, 1040; **¹H NMR** (400 MHz, CDCl₃): δ 8.02-7.95 (m, 4H), 7.57-7.51 (m,


2H), 7.44-7.34 (m, 4H), 7.23-7.15 (m, 4H), 5.75 (t, *J* 5.5, 2H), 3.44-3.30 (m, 4H); ¹³C NMR (100 MHz, CDCl₃): δ 166.2, 133.3, 132.6, 130.3, 129.9, 129.4, 128.6, 126.8, 70.5, 32.4; MS *m/z* (EI): 373 (2 [M]⁺), 128 (100 [M-2PhCOOH]⁺), 105 (85), 77 (72), 51 (32); HRMS (ESI) calcd. for C₂₄H₂₁O₄[M+H]⁺: 373.1434, found: 373.1439.

(-)-(1*S*,2*R*)-1,4-Diphenyl-2-hydroxyl-1-butyl benzoate (26)³


White solid; MW = 318.38 g / mol; R_F = 0.21 (Et₂O / pentane, 1: 3); [α]²⁰_D: -8 (*c* = 0.22 CH₂Cl₂); MP = 158-159 (CH₂Cl₂ / cyclohexane); IR (neat, cm⁻¹): 3477, 3028, 1720, 1451, 1316, 1272, 1177, 1113, 1027, 701; ¹H NMR (400 MHz, CDCl₃): δ 8.03-7.98 (m, 2H), 7.59-7.53 (m, 1H), 7.46-7.40 (m, 2H), 7.34-7.26 (m, 10H), 6.16 (d, *J* 5.8, 1H), 5.16 (d, *J* 5.8, 1H), 2.26 (broad s, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 165.7, 139.8, 136.8, 133.5, 130.3, 130.0, 128.8, 128.7, 128.6, 128.5, 128.4, 127.9, 127.3, 79.8, 76.9; MS *m/z* (EI): 318 (2 [M⁺]), 212 (51), 167 (15), 149 (3), 122 (5), 105 (100), 77 (64), 51 (10); HPLC Chiralcel OJ-H, eluent: 95:5 hexane / ⁱPrOH, flow rate: 1 mL / min: retention times 33.8 min ((1*R*,2*S*)-enantiomer) and 57.3 min ((1*S*,2*R*)-enantiomer).

cis-2,3-Bisbenzoyloxy-1,4-diphenylbutane¹⁰

White solid; MW = 422.49 g / mol; R_F = 0.39 (Et₂O / pentane, 1 : 2); MP = 241-239 °C (CH₂Cl₂ / cyclohexane); IR (neat, cm⁻¹): 2924, 2852, 1709, 1451, 1266, 1110, 1069, 710; ¹H NMR (400 MHz, CDCl₃): δ 8.01 (d, *J* 8.0, 4H), 7.56 (t, *J* 7.6, 2H), 7.43 (t, *J* 7.6, 4H), 7.29 (s, 10H), 6.49 (s, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 165.5, 136.2, 133.4, 130.1, 130.0, 128.78, 128.72, 128.4, 127.8, 77.6; HRMS (ESI) calcd. for C₂₈H₂₂O₄[M+H]⁺: 440.1856, found: 440.1851.



(-)-26



References

1. Quinchorine also exhibits this reactivity: I. Neda, T. Kaukorat, A. K. Fischer, *Eur. J. Org. Chem.* **2003**, 3784.
2. purchased from Buchler-GMBH, Braunschweig, Germany
3. D. Nakamura, K. Kakiuchi, K. Koga, R. Shirai, *Org. Lett.* **2006**, 8, 6139.
4. T. Kawabata, M. Nagato, K. Takasu, K. Fuji, *J. Am. Chem. Soc.* **1997**, 119, 3169.
5. T. Sano, K. Ohashi, T. Oriyama, *Synthesis* **1999**, 1141.
6. B. D. Glass, A. Goosen, C. W. McCleland, *J. Chem. Soc., Perkin Trans. 2* **1993**, 2175.
7. C. E. Wilson, H. J. Lucas, *J. Am. Chem. Soc.* **1936**, 58, 2396.
8. S. Mizuta, M. Sadamori, T. Fujimoto, I. Yamamoto, *Angew. Chem. Int. Ed.* **2003**, 42, 3383.
9. C. Mazet, V. Kohler, A. Pfaltz, *Angew. Chem. Int. Ed.* **2005**, 44, 4888.
10. S. Connelly, K. Line, N. Isupov Michail, A. Littlechild Jennifer, *Org. Biomol. Chem.* **2005**, 3, 3260.
11. C. Anchisi, A. Maccioni, A. M. Maccioni, G. Podda, *Gazz. Chim. Ital.* **1983**, 113, 73.
12. G. Tarkanyi, H. Jude, G. Palinkas, P. J. Stang, *Org. Lett.* **2005**, 7, 4971.
13. A. Miyafuji, K. Ito, T. Katsuki, *Heterocycles* **2000**, 52, 261